Spero reports Q3 2026 results, plans SP001 Phase 2 in IgG4-RD for Q2 2027
Spero said cash of $107.9 million should fund operations into the second half of 2029 as it advances its in-licensed CD40L antibody toward a mid-2027 Phase 2 start.
SEC filing
3 stories
Spero said cash of $107.9 million should fund operations into the second half of 2029 as it advances its in-licensed CD40L antibody toward a mid-2027 Phase 2 start.
SEC filing
Patrick Vink stepped down from Spero's board effective November 10, 2026, and William Ho was appointed to fill the vacancy the same day.
SEC filing
Spero disclosed in an SEC filing that its chief operating officer will step down at year end and remain as a paid consultant into early 2027.
SEC filing